Pharmacokinetics of amikacin in critically ill neonatal foals treated for presumed or confirmed sepsis.

The research study investigates the behavior of the drug amikacin in critically ill newborn foals treated for severe infections. The conclusions indicate that a certain dosage was found effective and that prematurity did not affect the survival rate of the studied foals.

Overview of the Research

• The study involved fourteen foals that were less than four days old. These young horses were suffering from severe health conditions such as septicaemia, pneumonia, and failure of passive immunoglobulin transfer. They were treated with two types of medications: amikacin sulphate, a type of aminoglycoside antibiotics, and either penicillin or ampicillin, both commonly used antibiotics.
• The dosage administered was 7.0 mg/kg bodyweight of amikacin every 8 hours. The researchers examined the concentration of the drug in the bloodstream at three different intervals – presumably before, during, and after the 8-hour dosing interval.

Key Findings

• In this study, it was observed that the dosage of amikacin was adequate for the newborn foals. This is important as determining how a drug behaves in the body (its pharmacokinetics) and finding the correct dosage are critical elements in ensuring the effectiveness of a treatment and minimizing side effects.
• The study also noted that prematurity in the foals did not influence their mortality rate. This means that being born prematurely did not affect how well the foals responded to the treatment or their chances of survival.
• Interestingly, all seven of the premature foals survived, while four out of the seven full term foals did not. However, the reasons for this difference in survival rates were not clearly stated in the abstract.

Additional Observations

• The study also noted that the three foals that developed uraemia (a condition characterized by high levels of urea and other waste products in the blood which is usually caused by kidney failure) had actually experienced urinary bladder rupture.
• However, the amikacin treatment was not related to this kidney complication, as no amikacin-induced nephrotoxicity (a toxic effect of the medication on the kidneys) was identified through clinical chemistry tests (examination of the levels of serum creatinine or blood urea nitrogen in the bloodstream) or post-mortem examinations.